

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/257800 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/366 (2006.01)
A61K 31/22 (2006.01) A61K 31/40 (2006.01)
A61K 31/655 (2006.01) A61K 31/404 (2006.01)
A61P 7/06 (2006.01) A61K 31/47 (2006.01)
A61P 13/12 (2006.01) A61K 31/505 (2006.01)
A61K 31/4412 (2006.01) A61K 31/63 (2006.01)
A61K 31/16 (2006.01) A61K 31/635 (2006.01)
A61K 31/166 (2006.01) A61K 33/06 (2006.01)
A61K 31/4418 (2006.01) A61K 33/244 (2019.01)
A61K 47/02 (2006.01) A61K 33/26 (2006.01)
A61K 9/48 (2006.01) A61K 31/66 (2006.01)
A61K 31/341 (2006.01)

(21) International Application Number:

PCT/US2021/037781

(22) International Filing Date:

17 June 2021 (17.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/041,226 19 June 2020 (19.06.2020) US
63/041,308 19 June 2020 (19.06.2020) US
63/155,013 01 March 2021 (01.03.2021) US

(71) Applicants: **AKEBIA THERAPEUTICS, INC.** [US/US];
245 First Street, Suite 1400, Cambridge, MA 02142 (US).
MITSUBISHI TANABE PHARMA CORPORATION
[JP/JP]; 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka,
541-8505 (JP).

(72) Inventors: **CHAVAN, Ajit**; C/o Akebia Therapeutics, Inc.,
245 First Street, Suite 1400, Cambridge, MA 02142 (US).
SAWANT, Rishikesh; C/o Akebia Therapeutics, Inc., 245
First Street, Suite 1400, Cambridge, MA 02142 (US).
KOKADO, Yoshimasa; C/o Mitsubishi Tanabe Pharma
Corporation, 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi,
Osaka, 541-8505 (JP). **NANJO, Takehiro**; C/o Mitsubishi
Tanabe Pharma Corporation, 3-2-10, Dosho-machi, Chuo-
ku, Osaka-shi, Osaka, 541-8505 (JP). **KINOSHITA, Shu-
ji**; C/o Mitsubishi Tanabe Pharma Corporation, 3-2-10,
Dosho-machi, Chuo-ku, Osaka-shi, Osaka, 541-8505 (JP).
KONISHI, Naomi; C/o Mitsubishi Tanabe Pharma Corpo-
ration, 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka,
541-8505 (JP).

(74) Agent: **ESPINO, Christine, G.** et al.; Proskauer Rose LLP,
One International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT

(57) Abstract: Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.



WO 2021/257800 A1